Atopic dermatitis is a chronic inflammatory skin disease occurs from a complex connection between environmental, immunologic, genetic, and pharmacologic factors. Atopic dermatitis is also known as atopic eczema, which is identified by pruritus (an unpleasant sensation that evokes the desire to scratch), scratching, redness, scaling, and loss of the skin surface. Atopic dermatitis is considered to be the first indication of other common atopic diseases, like allergic rhinitis, and asthma, this event is also known as the atopic march. It is one of the most common skin diseases, around the world, where different cases ranging from 10–20% in children, and 1–3% in adults has been noticed. The key goals of disease management in atopic dermatitis involve avoiding the triggering of disease, different measures to be taken to restore skin barrier function and the use of anti-inflammatory drugs. Treatment or measures taken to avoid contracting atopic dermatitis disease are, avoid using soap & other irritants, and certain creams & ointments which will provide relief from the itching as well rashes. Atopic Dermatitis Drugs Market accounted 4.4 USD billion in 2020 and is expected to reach 6.8 USD billion by 2030 growing with a CAGR of 4.5% during the forecast period.

Market Segmentation:

The global atopic dermatitis drugs market is segmented by therapy type into phototherapy and directed therapy. By route of administration the market is bifurcated into injectable, oral, and topical.  By the end-user, the market is categorized into hospitals, clinics, and research labs. By geography, the atopic dermatitis drugs market is bifurcated into North America, Asia Pacific, Europe, and the RoW. 

Market Dynamics and Factors:

Launch of more biologics & small molecules, premium-priced drugs replacing generic first-line and second-line therapeutics, growing incidence of AD, and improved diagnostics are driving the growth of the atopic dermatitis drugs market. Rise in awareness regarding the availability of treatments for the disease has helped the market to emerge over the past few years. The anticipated launch of the first biologic drug like Sanofi/Regeneron’s dupilumab for the treatment of moderate to severe disease will further boost the atopic dermatitis drugs market. The High cost of therapeutics is one of the restraints in the growth of the atopic dermatitis drugs market. However, affordable healthcare measures are being incorporated across all major regions, and change in pricing strategies of companies as well as reimbursement scenario is expected to show growth in the atopic dermatitis drugs market.

Geographic Analysis:

Among the major markets, Latin America has dominated the global arena in 2016. The U.S. market is anticipated to register healthy CAGR during the forecast period. Also Increase incidence of atopic dermatitis, rising treatment rate, and inflated drug prices are some of the key factors for increasing revenue generation in the country. Japan is projected to register the highest CAGR during the same period. Countries such as the U.K. and Spain are expected to hold prominent positions in the global atopic dermatitis drugs market throughout the forecast period.

Competitive Scenario:

The major market players in the global atopic dermatitis drugs market are Meda Pharmaceuticals, Leo Pharma, Valent Pharmaceutical Inc., Encore Dermatology, and Bayer Ag.

Atopic Dermatitis Drugs Market Report Scope